GILD
Income statement / Annual
Last year (2024), Gilead Sciences, Inc.'s total revenue was $28.75 B,
an increase of 6.04% from the previous year.
In 2024, Gilead Sciences, Inc.'s net income was $480.00 M.
See Gilead Sciences, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$28.75 B |
$27.12 B |
$27.28 B |
$27.31 B |
$24.69 B |
$22.45 B |
$22.13 B |
$26.11 B |
$30.39 B |
$32.64 B |
| Cost of Revenue |
$6.25 B
|
$6.50 B
|
$5.66 B
|
$6.60 B
|
$4.57 B
|
$4.68 B
|
$4.85 B
|
$4.37 B
|
$4.26 B
|
$4.01 B
|
| Gross Profit |
$22.50 B
|
$20.62 B
|
$21.62 B
|
$20.70 B
|
$20.12 B
|
$17.77 B
|
$17.27 B
|
$21.74 B
|
$26.13 B
|
$28.63 B
|
| Gross Profit Ratio |
0.78
|
0.76
|
0.79
|
0.76
|
0.81
|
0.79
|
0.78
|
0.83
|
0.86
|
0.88
|
| Research and Development Expenses |
$5.91 B
|
$6.92 B
|
$4.98 B
|
$5.36 B
|
$5.04 B
|
$9.11 B
|
$5.02 B
|
$3.73 B
|
$5.10 B
|
$3.01 B
|
| General & Administrative Expenses |
$0.00
|
$5.26 B
|
$4.90 B
|
$4.51 B
|
$4.36 B
|
$3.60 B
|
$4.06 B
|
$3.88 B
|
$3.40 B
|
$3.43 B
|
| Selling & Marketing Expenses |
$0.00
|
$826.00 M
|
$778.00 M
|
$735.00 M
|
$795.00 M
|
$784.00 M
|
$587.00 M
|
$600.00 M
|
$618.00 M
|
$601.00 M
|
| Selling, General & Administrative Expenses |
$6.09 B
|
$6.09 B
|
$5.67 B
|
$5.25 B
|
$5.15 B
|
$4.38 B
|
$4.06 B
|
$3.88 B
|
$3.40 B
|
$3.43 B
|
| Other Expenses |
$8.84 B
|
$0.00
|
-$581.00 M
|
-$639.00 M
|
-$1.42 B
|
$1.87 B
|
$676.00 M
|
$523.00 M
|
$428.00 M
|
$154.00 M
|
| Operating Expenses |
$20.84 B
|
$13.67 B
|
$10.65 B
|
$10.61 B
|
$10.19 B
|
$13.49 B
|
$9.07 B
|
$7.61 B
|
$8.50 B
|
$6.44 B
|
| Cost And Expenses |
$27.09 B
|
$19.69 B
|
$16.31 B
|
$17.21 B
|
$14.76 B
|
$18.16 B
|
$13.93 B
|
$11.98 B
|
$12.76 B
|
$10.45 B
|
| Interest Income |
$281.00 M
|
$0.00
|
$935.00 M
|
$1.00 B
|
$984.00 M
|
$995.00 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$977.00 M
|
$944.00 M
|
$935.00 M
|
$1.00 B
|
$984.00 M
|
$995.00 M
|
$1.08 B
|
$1.12 B
|
$964.00 M
|
$688.00 M
|
| Depreciation & Amortization |
$0.00
|
$2.69 B
|
$2.10 B
|
$2.05 B
|
$1.48 B
|
$1.40 B
|
$1.43 B
|
$1.29 B
|
$1.16 B
|
$1.10 B
|
| EBITDA |
$1.66 B |
$10.50 B |
$8.85 B |
$11.33 B |
$4.13 B |
$7.56 B |
$10.31 B |
$15.93 B |
$19.22 B |
$23.45 B |
| EBITDA Ratio |
0.06
|
0.39
|
0.38
|
0.35
|
0.34
|
0.27
|
0.4
|
0.56
|
0.59
|
0.68
|
| Operating Income Ratio |
0.06
|
0.28
|
0.27
|
0.27
|
0.28
|
0.19
|
0.37
|
0.54
|
0.58
|
0.68
|
| Total Other Income/Expenses Net |
-$972.00 M
|
-$746.00 M
|
-$1.52 B
|
$872.00 M
|
-$2.40 B
|
$873.00 M
|
-$401.00 M
|
-$595.00 M
|
-$536.00 M
|
-$534.00 M
|
| Income Before Tax |
$690.00 M
|
$6.86 B
|
$5.81 B
|
$8.28 B
|
$1.67 B
|
$5.16 B
|
$7.80 B
|
$13.53 B
|
$17.10 B
|
$21.66 B
|
| Income Before Tax Ratio |
0.02
|
0.25
|
0.21
|
0.3
|
0.07
|
0.23
|
0.35
|
0.52
|
0.56
|
0.66
|
| Income Tax Expense |
$211.00 M
|
$1.25 B
|
$1.25 B
|
$2.08 B
|
$1.58 B
|
-$204.00 M
|
$2.34 B
|
$8.89 B
|
$3.61 B
|
$3.55 B
|
| Net Income |
$480.00 M
|
$5.67 B
|
$4.59 B
|
$6.23 B
|
$89.00 M
|
$5.39 B
|
$5.46 B
|
$4.63 B
|
$13.50 B
|
$18.11 B
|
| Net Income Ratio |
0.02
|
0.21
|
0.17
|
0.23
|
0
|
0.24
|
0.25
|
0.18
|
0.44
|
0.55
|
| EPS |
0.38 |
4.54 |
3.66 |
4.96 |
0.0708 |
4.24 |
4.2 |
3.54 |
10.08 |
12.37 |
| EPS Diluted |
0.38 |
4.5 |
3.64 |
4.93 |
0.0705 |
4.22 |
4.17 |
3.51 |
9.94 |
11.91 |
| Weighted Average Shares Out |
$1.25 B
|
$1.25 B
|
$1.26 B
|
$1.26 B
|
$1.26 B
|
$1.27 B
|
$1.30 B
|
$1.31 B
|
$1.34 B
|
$1.46 B
|
| Weighted Average Shares Out Diluted |
$1.26 B
|
$1.26 B
|
$1.26 B
|
$1.26 B
|
$1.26 B
|
$1.28 B
|
$1.31 B
|
$1.32 B
|
$1.36 B
|
$1.52 B
|
| Link |
|
|
|
|
|
|
|
|
|
|
